Navigation Links
MEDIA INVITED: Immunomic Therapeutics, Inc., Talks Vital Vaccine Technology Advancement at Biotech Showcase 2016

HERSHEY, Pa. and ROCKVILLE, Md., Jan. 12, 2016 /PRNewswire/ -- Following one of the largest upfront payments for rights to an early-stage allergy vaccine technology, Immunomic Therapeutics, Inc. (ITI) will share the projections for their potentially game-changing DNA vaccine platform with investors at the Biotech Showcase™ 2016 on Wednesday.

The talk will focus on the LAMP-vax™ platform, a unique vaccine technology that relies on the body's own natural biochemistry to increase vaccine effectiveness. Late last year, the Japanese firm, Astellas Pharma purchased the rights to apply LAMP-vax to human allergy worldwide for $300M. Astellas is working to produce a pipeline of allergy therapies, including a LAMP-vax based vaccine for peanut allergy, and ITI is now taking aim at cancer immunology. On Wednesday, ITI's Chief Financial Officer, Eric Winzer, will share LAMP-vax development plans and discuss anticipated implications on the future healthcare landscape.Who:Eric Winzer, CFO, Immunomic Therapeutics, Inc. What: 

Biotech Showcase 2016: LAMP-vax Vaccines, Next Generation ImmunotherapiesWhen: 11:45 a.m. on Wed., Jan. 13, 2016Where: 

E-Davidson, Fourth FloorParc 5555 Cyril Magnin StreetSan Francisco, CA 94102


About LAMP-vax platform

The LAMP-vax platform is a breakthrough technology that has the potential to fundamentally improve the use of vaccines across a wide variety of diseases.  LAMP-vax is a next-generation DNA vaccine that stimulates an immune response against a particular protein by injecting the DNA encoding the protein rather than the protein itself.  However, unlike older, conventional DNA vaccines, LAMP-vax includes the DNA sequence encoding Lysosomal Associated Membrane Protein (LAMP).  This allows DNA vaccines developed, based on the LAMP-vax platform, to utilize the body's natural biochemistry to develop a more complete immune response compared to conventional DNA vaccines.  Unlike conventional DNA vaccines that primarily elicit a cytotoxic T cell immune response, vaccines developed using LAMP-vax initiate a more complete immune response, including antibody production, cytokine release and critical immunological memory.  The ability to activate a complete immune response gives LAMP-vax technology potential across a number of diseases, including cancer immunotherapy, allergy and infectious diseases.

About Immunomic Therapeutics
Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company dedicated to pioneering vaccines that transform lives.  Headquartered in Hershey, PA with lab facilities in Rockville, MD, ITI is developing next-generation vaccines based on patented LAMP Technology.  Its LAMP-vax vaccine platform significantly increases the immune response to nucleic acid vaccines and simplifies vaccine design and delivery for safer, more cost-effective therapies.  LAMP constructs have been validated in human clinical trials for cancer and have been applied to targets like allergy, cancer and infectious diseases.  Immunomic Therapeutics' vision is to have regulatory approved products in pollen allergy, food allergy, cancer, and animal health. For information about Immunomic Therapeutics and LAMP Technology, visit


SOURCE Immunomic Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved

Related medicine technology :

1. Survey Shows That One Third Of Women (Ages 20 to 39) Polled Have Removed A Photo From Social Media To Hide Their Acne(1)
2. Dario Diabetes Management Solution Garners Global Media Coverage
3. New Study Outlines how Pharmaceutical Industry Can Boost Performance through Social Media Listening Programs
4. Allergan Reaches Settlement with New York Attorney Generals Office in Memantine Immediate Release Litigation
5. Report: Rapid Rise in Cost of Specialty Drugs Exceeds Median Family Income
6. Global and China Contrast Media / Contrast Agent Market Projections for 2015 - 2020
7. SST Group to show HIPAA/HITECH compliant DVM-EZ DICOM Virtual Media Creator for distribution of patient images and results at RSNA, booth 3254
8. Media Reports Mischaracterize Specialty Pharmacies
9. NuGene International, Inc. Files Provisional Patent Applications to Enhance Wound Treatment by Combining Micro-Current Electro-Active Dressings with Human Adipose-Derived Stem Cell Media
10. U.S. Diaphragm Pacing Study in ALS Continues Enrollment: The Post Approval Studys (PAS) Interim Data Showed Device Safety and Median Survival Post-Implant of 20.9 months
11. Contrast Media Injector Market - Global Market Research 2015-2019 - Reportlinker Review
Post Your Comments:
(Date:8/5/2020)... (PRWEB) , ... August 04, 2020 , ... Fifty six ... to respond more quickly and effectively to a healthcare crisis like COVID-19, according to ... is one of the most important issues for older voters this year,” says Mary ...
(Date:8/5/2020)... ... August 05, 2020 , ... ... , Best Practices During COVID-19, An FDAnews Webinar, Wednesday, Aug. 19, 2020, ... a controlled cleanroom is never simple and COVID-19 has made it more ...
(Date:8/3/2020)... ... August 03, 2020 , ... Seattle’s Infectious ... to amend and restate IDRI’s license with Immune Design, a wholly owned subsidiary ... the amendment, the parties have agreed to modify the licensed fields and indications ...
Breaking Medicine Technology:
(Date:8/5/2020)... ... August 05, 2020 , ... Atlanta Magazine partnered with Castle ... the “Top Doctor” survey. The mission of Castle Connolly Medical Ltd. is to ... and key medical leaders were asked to identify outstanding doctors in their respective ...
(Date:8/5/2020)... ... August 05, 2020 , ... Hypoglycemia (low ... prolonged length of hospital stay, or even death. A researcher at the VA ... Type 2 diabetes to see if the use of continuous glucose monitoring devices ...
(Date:8/5/2020)... ... August 05, 2020 , ... CentrAlert, Inc. today announced the ... to essential COVID-19 information. Know NOW!, which is available for Apple and ... them in one easy-to-use mobile application. , “When COVID-19 first hit, there was so ...
(Date:8/5/2020)... Texas (PRWEB) , ... August 04, 2020 , ... ... older adults living with memory impairment, has announced the Best Memory Care Facilities ... access to experts, facility features and amenities. , According to the ...
(Date:8/3/2020)... , ... August 03, 2020 , ... ... the launch of its newest product, CoverageCoach. The site provides a simple and ... purchase insurance products. The company sees CoverageCoach as an important expansion for the ...
Breaking Medicine News(10 mins):